Sionna Therapeutics Appoints Caroline Stark Beer as Chief Business Officer 

Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company developing medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, has appointed Caroline Stark Beer, MBA, as its Chief Business Officer.

Caroline brings more than 20 years of experience in the life science industry. She was most recently CBO at Jnana Therapeutics until Jnana’s sale to Otsuka Pharmaceutical. Caroline led the team responsible for corporate and business development, alliance management, legal contracts, new product planning, and communications. Before Jnana, she spent over a decade at Alnylam Pharmaceuticals; in her final role there, she served as VP of Business Development. During this time, she led the formation of partnerships including a 5-year collaboration with Regeneron Pharmaceuticals to discover and develop new RNA interference (RNAi) therapeutics. 

“We are delighted to welcome Caroline to our executive team at such a pivotal stage for Sionna,” said Mike Cloonan, President and Chief Executive Officer of Sionna. “Caroline’s exceptional experience, leadership, and value creation mindset will enhance our corporate development efforts as we continue to advance toward our goal of delivering innovative and transformative therapies for people living with CF.” 

“I believe that the most meaningful growth happens in organizations where scientific excellence and business strategy work seamlessly together while focusing on the patient as the North-Star. Sionna embodies this approach, which is why I’m thrilled to join the company,” said Caroline. “I look forward to helping Sionna execute on its mission, striving toward enhanced options for CF patients.”